Created for surgeons— by surgeons.
Imbed Biosciences Inc. is a privately held medical device company emerging as a leader in the development of advanced therapies for the treatment of burns, chronic ulcers, gastro-intestinal defects, and soft-tissue repair.
The company has a portfolio of products in development based on its patented MicroLyte® Matrix technology that presents bioactive molecules on tissue surfaces to combat local pain and infections. The microscale matrix accelerates cell migration and reduces antibiotic/opioid abuse.
The world’s first and only fully-synthetic, antimicrobial, and bioresorbable matrix.
Microbial contamination is a threat to healing of all surgical wounds. Microlyte® Surgical contains bacteria-killing antimicrobial silver. Reduction of bacterial bioburden may reduce microbial colonization and risks of wound infection. This addition of ionic and metallic silver provides rapid, effective, and sustained antimicrobial activity.
Microlyte® Surgical absorbs wound fluid and transforms into a bioresorbable material that intimately contours to the underlying surgical wound. It maintains a physiologically moist microenvironment. In vitro and in vivo, studies indicate that components of the matrix allow cell growth and neovascularization. 1,2,3
Easy to use, conforms to any size or shape. Microlyte® Surgical is as easy as peel and place. It is indicated for virtually all acute, chronic, and traumatic wound types.
Next Generation Antimicrobial Matrix
Microlyte® Matrix absorbs wound fluid and transforms into a bioresorbable gel that intimately contours to the underlying wound bed. It maintains a physiologically moist microenvironment. In vitro and in vivo, studies indicate that components of the matrix allow cell growth and neovascularization.
Next Generation SedLine Features:
Interview with Imbed at SAWC Fall 2021
Imbed Leadership Team
CEO / Board of Directors / Co-Founder / Executive Team
Agarwal is leading the development and commercialization of Imbed’s platform technologies that he co-invented during his post-doctoral research at the University of Wisconsin from 2007-2012. He brings 12 years of research experience in developing advanced biomaterials, with a PhD in Chemical and Biological Engineering from Iowa State University (Ames, IA). In 2009-2010, Agarwal received one year training to commercialize scientific innovations as an Entrepreneurial Postdoctoral Fellow of the Ewing Marion Kauffman Foundation (Kansas City, MO). Agarwal has BS and MS in Biochemical Engineering and Biotechnology from Indian Institute of Technology, Delhi.
Board of Directors / Co-Founder
Prof. Michael Schurr, MD is a burn and trauma surgeon and general surgeon at Mission Hospitals, Asheville, NC. Dr. Schurr is board certified in general surgery and surgical critical care. He has joined Mission Hospitals as Director of Inpatient Surgical Wound Care in Dec 2014. Prior to that he practiced for more than 15 years at the School of Medicine in University of Wisconsin-Madison and University of Colorado-Denver. He brings 27 years of experience in advanced care of chronic ulcers, burns and trauma wounds. He has successfully led clinical trials of several advanced wound dressings and hernia surgical meshes.
Board of Directors / WISC Partners
David Guinther is a proven entrepreneur and senior executive, a turnaround specialist, a company founder and builder, a management consultant, a board member, an executive coach, and a social entrepreneur. He has considerable experience in Angel, VC, and IPO funding rounds, with M&A, and most importantly, in delivering liquidity events to investors. His industry experience is largely in technology, although his recent work includes medical and consumer products.
Board of Directors
Jeff Hanson has over 30 years of financial/professional service, advisory, entrepreneurial, and institutional asset management operating experience. His specialized advisory firm, Hanson Advisors, partners with businesses in financial services, private equity, asset management, insurance, healthcare, technology, and other service businesses/ventures across a full range of strategic, operating, organizational and partnership initiatives. Defining, achieving, sustaining, and re-inventing “success” throughout business, market, and organizational life cycles is a key focus with client-partners – particularly private partnerships and companies/ventures in transition.
Board of Directors
Elizabeth has functioned as the COO and founder of several companies. In 2010 she started Burnett Taylor Consulting, LLC, an advisory firm that counsels high net worth clients on their investments. Before founding her own company, Elizabeth was the COO of a $5BN start-up division within Citadel Investment Group. Prior to that position, she was the COO and co-founder of Tala Investments, LP, a value hedge fund. Elizabeth received her BA from Princeton University and her MBA from Harvard Business School.